NDF Research have updated their coverage note titled “Dimerix – DMX-200’s credibility increases”
The report is available here.
Dimerix is pleased to announce the appointment of Associate Professor David Packham to the role of Chief Medical Officer (CMO), and has provided an update on the development plan for its lead therapeutic program DMX-200 for Chronic Kidney Disease (CKD).
Full details are available in the ASX announcement here.
Dimerix Limited has raised an additional $4.5 million through the issue of 37,500,000 shares at 12 cents per share to wholesale and institutional clients of Westar Capital and Baker Young Stockbrokers who acted as Joint Lead managers to the Issue.
Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company today announces results from its 1 for 2 pro-rata non-renounceable Entitlement Offer of fully paid ordinary shares in Dimerix announced on 6 December 2017, opened on 13 December 2017 and closed on 19 January 2018.
View the full release here.
The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 at 7:00pm AEDT (Sydney time).
Funds raised are important for the commercialisation of DMX-200 across the Chronic Kidney Disease areas of FSGS and Diabetic Nephropathy
An Entitlement and Acceptance form has been mailed to shareholders, and […]
Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program targeting Chronic Kidney Disease (CKD).
The study found a newly formulated extended release tablet of DMX-200 taken twice daily (against three times daily for the previous formulation) increases the duration of release of DMX-200 in […]
CEO Kathy Harrison discusses the exciting data from the Dimerix Phase 2a study in patients with Chronic Kidney Disease (CKD) in this interview from Bio-Europe 2017, Berlin, November 2017.